A5103130569- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Viral-associated cancers and disorders
- Ferroptosis and cancer prognosis
- Liver physiology and pathology
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- MRI in cancer diagnosis
- Liver Disease and Transplantation
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Hepatitis B Virus Studies
Hunan Provincial People's Hospital
2018-2024
Hunan Normal University
2018-2024
The prediction model of postoperative survival for single large and huge hepatocellular carcinoma (SLH-HCC, diameter > 5.0 cm) without portal vein tumour thrombus has not been well established. This study aimed to develop novel nomograms predict recurrence these patients.Data from 2469 patients with SLH-HCC who underwent curative resection January 2005 December 2015 in China were retrospectively collected. Specifically, recurrence-free (RFS) overall (OS) using data a training cohort...
Liver cancer is one of the most common malignant tumors, and ranks as fourth leading cause death worldwide. Microvascular invasion (MVI) considered important factors for recurrence poor prognosis liver cancer. Thus, accurately identifying MVI before surgery great importance in making treatment strategies predicting patients with hepatocellular carcinoma (HCC). Radiomics an emerging field, aims to utilize artificial intelligence software develop methods that may contribute diagnosis,...
Summary Background Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC). Aim To compare the effect different anti‐PD‐1 therapies as first‐line treatments uICC. Methods This study included 318 patients who received chemotherapy alone (Chemo), plus (ICI‐chemo), targeted (ICI‐target) or and (ICI‐target‐chemo) first line uICC from 22 centres in China. The primary endpoint was progression‐free survival...
The evidence of radiofrequency ablation (RFA) following transarterial chemoembolisation (TACE) combined with sorafenib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited. Patient responses to this treatment vary because the heterogeneous nature RHCC, making it important identify patients who are most likely benefit from combination therapy. aim study was evaluate efficacy RFA TACE and RHCC.This retrospective, multicentre, cohort included 363 RHCC underwent...
Abstract Background Radiofrequency ablation (RFA) is considered as a convenient treatment with mild damage in treating recurrent hepatocellular carcinoma (RHCC). However, for patients high risk of progression after RFA still needs new strategies to decrease the repeat recurrence. Methods A total 460 RHCC within Milan criteria four institutions were enrolled. 174 pairs enrolled propensity score matching (PSM). Overall survival (OS) and tumor-free (TFS) compared between two groups....
Although immunotherapy combined with targeted therapy can be effective for hepatocellular carcinoma (HCC), not all HCC patients respond to this treatment. Models predicting tumour response in receiving are lacking.A total of 221 from two independent prospective cohorts were retrospectively reviewed. The randomly divided into training and validation at a ratio 7:3. Standard clinical data collected each patient, including age, sex, hepatitis B infection status, laboratory tests, immune...
Journal Article Adjuvant transarterial chemoembolization for intermediate-stage hepatocellular carcinoma with microvascular invasion Get access Xiao-Hui Wang, Wang Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital (First Affiliated Normal University), Changsha, China https://orcid.org/0000-0003-0544-2599 Search other works by this author on: Oxford Academic Google Scholar Qun-Fang Zhou, Zhou Minimally Invasive Interventional Radiology, and Second Guangzhou Medical...
Abstract Background Characteristic symptoms and signs are often absent in patients with hepatocellular carcinoma (HCC). As a result, many not diagnosed until their tumors have grown to large (> 5cm) or huge sizes 10cm). Liver resection has traditionally been reserved for small HCC, but more recently it is being used tumors. The aim of this study was determine risk predictors recurrence, patterns survival rates HCC who underwent curative liver resection. Materials methods We...
The clinical data of 7 patients diagnosed with mixed neuroendocrine-nonneuroendocrine neoplasm were analyzed in the Department Hepatobiliary Surgery Hunan Provincial People's Hospital from January 2016 to December 2022. Among patients, 5 male and 2 female, an average age 59.3 years. Its characteristics are similar malignant ampulla tumors, it is difficult differentiate them. preoperative puncture biopsy positivity rate low, making diagnose preoperatively, prognosis worse.Comprehensive...
Background: Effectiveness of Lenvatinib on infiltrative hepatocellular carcinoma (HCC) is unsatisfactory. Hepatic arterial infusion chemotherapy (HAIC) and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced HCC. This study aimed to compare the efficacy safety HAIC combined PD-1 versus HCC.Methods: 173 patients received with (HAIC+Len group) 128 (HAIC+Len+PD-1 from three institutions in China enrolled. Overall survival (OS), progression-free (PFS) were...
<p>Supplementary Methods, Supplementary Figure S1-4, Table S1-8</p>
<p>Supplementary Methods, Supplementary Figure S1-4, Table S1-8</p>
<div>AbstractPurpose:<p>We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).</p>Patients Methods:<p>This nonrandomized, open-label, multicenter, phase II study enrolled HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous 200 mg (for bodyweight ≥50 kg) 3 mg/kg...
<div>AbstractPurpose:<p>We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).</p>Patients Methods:<p>This nonrandomized, open-label, multicenter, phase II study enrolled HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous 200 mg (for bodyweight ≥50 kg) 3 mg/kg...